Comprehensively, with these findings, we propose that simultaneous targeting of both CLU-mediated mitophagy and PPARGC1A-dependent mitochondrial biogenesis could be helpful in overcoming drug resistance to cisplatin and enhancing mitophagy-associated cell death for better therapeutic outcomes in oral cancer. Here, PPARGC1A is linked to lip and oral cavity carcinoma.